Andere Sprachen Vaxcyte, Inc.

Aktien

A2P6R6

US92243G1085

PCVX

Biotechnologie

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:22:43 22.01.2025			% 5 Tage	% 1. Jan.
87,10 ^USD	-1,22 %		-2,59 %	+6,25 %

07.01.	Vaxcyte Insider verkaufte Aktien im Wert von 427.923 US-Dollar, wie aus einem kürzlich bei der SEC eingereichten Dokument hervorgeht	MT
19.12.	Vaxcyte Insider verkaufte Aktien im Wert von $710.249, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Vaxcyte : January Investor Presentation	13.01.
Vaxcyte Insider Sold Shares Worth $427,923, According to a Recent SEC Filing	07.01.
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm	07.01.
Vaxcyte Insider Sold Shares Worth $710,249, According to a Recent SEC Filing	19.12.
Vaxcyte : December Investor Presentation	03.12.
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants	03.12.
Vaxcyte, Inc. Initiates Phase 2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Infants	03.12.
Vaxcyte, Inc. Announces Amended and Restated the Original Lease and Enters into Sublease Agreement with Iovance Biotherapeutics, Inc	21.11.
Vaxcyte Insider Sold Shares Worth $686,518, According to a Recent SEC Filing	19.11.
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs	12.11.
Vaxcyte, Inc. Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs	12.11.
Vaxcyte : Reports Third Quarter 2024 Financial Results and Provides Business Update Form 8 K	05.11.
Vaxcyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	05.11.
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update	05.11.
Certain Restricted Stock Units of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 4-NOV-2024.	04.11.
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 4-NOV-2024.	04.11.
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 4-NOV-2024.	04.11.
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 4-NOV-2024.	04.11.
Vaxcyte Insider Sold Shares Worth $4,846,508, According to a Recent SEC Filing	22.10.24
Vaxcyte Insider Sold Shares Worth $6,283,861, According to a Recent SEC Filing	03.10.24
Vaxcyte Insider Sold Shares Worth $927,551, According to SEC Filing	19.09.24
Vaxcyte Insider Sold Shares Worth $1,159,635, According to a Recent SEC Filing	18.09.24
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference	11.09.24
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Apple, Oracle, Progressive, Dollar Tree...	10.09.24
Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...	10.09.24

Werden Sie Mitglied, um Zugang zu mehr Nachrichten zu erhalten.

100% kostenlose Registrierung

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vaxcyte, Inc.

Aktien

A2P6R6

US92243G1085

PCVX

Biotechnologie

Andere Sprachen

Filter